Kronos Bio Announces Participation in Upcoming Investor Conferences
Kronos Bio, Inc. (Nasdaq: KRON) will have President and CEO Norbert Bischofberger participate in investor conferences. Bischofberger will appear at the Jefferies Healthcare Conference on June 8, 2022, at 4:30 p.m. ET, and at the Goldman Sachs 43rd Annual Global Healthcare Conference on June 15, 2022, at 3:20 p.m. PT. Live webcasts will be accessible on the Kronos Bio website, with replays available for 30 days post-event. Kronos Bio focuses on therapies for cancer treatment, notably developing entospletinib for NPM1-mutated AML and KB-0742 for MYC-amplified tumors.
- None.
- None.
SAN MATEO, Calif. and CAMBRIDGE, Mass., June 01, 2022 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer and other serious diseases, today announced that President and Chief Executive Officer Norbert Bischofberger, Ph.D., will participate in fireside chats at the following investor conferences:
- Jefferies Healthcare Conference on Wednesday, June 8, 2022, at 4:30 p.m. ET in New York; and
- Goldman Sachs 43rd Annual Global Healthcare Conference on Wednesday, June 15, 2022, at 3:20 p.m. PT in Rancho Palos Verdes, California.
Live webcasts of the fireside chats will be available on the Investors and Media section of the Kronos Bio website at www.kronosbio.com. A replay of the webcasts will be archived and available for 30 days following the event.
About Kronos Bio, Inc.
Kronos Bio is a clinical-stage biopharmaceutical company dedicated to discovering and developing therapies that seek to transform the lives of those affected by cancer and other serious diseases. The company focuses on targeting dysregulated transcription factors and the regulatory networks within cells that drive cancerous growth. Kronos Bio’s lead investigational therapy is entospletinib, a selective inhibitor targeting spleen tyrosine kinase (SYK) in development for the frontline treatment of NPM1-mutated acute myeloid leukemia (AML). The company is also developing KB-0742, an oral inhibitor of cyclin dependent kinase 9 (CDK9), for the treatment of MYC-amplified solid tumors.
Kronos Bio is based in San Mateo, Calif., and has a research facility in Cambridge, Mass. For more information, visit www.kronosbio.com or follow the company on LinkedIn.
Company Contact:
Marni Kottle
Kronos Bio
650-900-3450
mkottle@kronosbio.com
Investors:
Claudia Styslinger
Argot Partners
212-600-1902
kronosbio@argotpartners.com
Media:
Sheryl Seapy
Real Chemistry
949-903-4750
sseapy@realchemistry.com
FAQ
When will Kronos Bio participate in investor conferences?
Who is the CEO of Kronos Bio?
What is entospletinib used for?
Where can I watch the Kronos Bio webcasts?
What is the focus of Kronos Bio's research?
